Lucid Diagnostics Inc.
LUCD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | 0.06 | -0.01 | -0.03 |
| FCF Yield | -108.29% | -56.11% | -62.19% | -9.57% |
| EV / EBITDA | -0.91 | -1.11 | -0.53 | -5.11 |
| Quality | ||||
| ROIC | -172.84% | -374.55% | -215.98% | -50.09% |
| Gross Margin | -90.20% | -249.18% | -858.62% | -17.00% |
| Cash Conversion Ratio | 0.97 | 0.62 | 0.53 | 0.63 |
| Growth | ||||
| Revenue 3-Year CAGR | 125.90% | 69.34% | – | – |
| Free Cash Flow Growth | -35.56% | -7.99% | -65.10% | -229.21% |
| Safety | ||||
| Net Debt / EBITDA | 0.02 | 0.07 | 0.38 | 1.96 |
| Interest Coverage | -1,771.23 | -116.54 | -7,021.38 | -41.61 |
| Efficiency | ||||
| Inventory Turnover | 24.24 | 30.50 | 32.56 | 1.19 |
| Cash Conversion Cycle | -5.73 | -30.60 | -78.98 | -476.06 |